首页 > 抗体蛋白 > 抗体
FITC anti-mouse CD49b (pan-NK cells) Antibody
产品名称:
FITC anti-mouse CD49b (pan-NK cells) Antibody
产品类别:
抗体
产品编号:
108905
产品应用:
108905
[价格]
规格 价格 库存
50µg ¥ 1414 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-propagated NK1.1+ cells from C57BL/6 mice
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen in vitro. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity2 and immunohistochemical staining5 of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections10. The binding of DX5 antibody to splenic NK cells can be blocked by HMa2 antibody.

Application References

(PubMed link indicates BioLegend citation)
  1. Arase H, et al. 2001. J. Immunol. 167:1141. (FC)
  2. Sepulveda H, et al. 1999. J. Immunol. 163:1133.
  3. Norian LA and Allen PM. 2004. J. Immunol. 173:835. (FC)
  4. Andoniou CE, et al. 2005. Nature Immunology 6:1011.
  5. Oertelt S, et al. 2006. J. Immunol. 177:1655. (IHC) PubMed
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370.
  7. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  8. Qui Q, et al. 2010. J. Immunol. 184:1681. (FC) PubMed
  9. Busche A, et al. 2011. J. Immunol. 186:2918. PubMed
  10. Kim HR, et al. 2011. Nephrology 16:545. (IHC) PubMed
  11. Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed
  12. Younos IH, et al. 2012. Int Immunopharmacol. 13:245. PubMed
  13. Honjo K, et al. 2012. PNAS. PubMed.
  14. Huang HN, et al. 2013. Biomaterials. 34:10151. PubMed
Product Citations
  1. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  2. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
  3. Johnson KD, et al. 2022. Blood Adv. 6:1464. PubMed
  4. Wu L, et al. 2022. Front Immunol. 13:860761. PubMed
  5. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
  6. An SB, et al. 2022. Nat Commun. 13:5669. PubMed
  7. Chung YM, et al. 2022. Am J Cancer Res. 12:1241. PubMed
  8. Sharma NS, et al. 2020. J Clin Invest. 130:451. PubMed
  9. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  10. Kuns R, et al. 2009. Blood. 113:5999. PubMed
  11. K?chl R, et al. 2020. Elife. 9:00. PubMed
  12. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  13. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
  14. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  15. Chung YM, et al. 2021. J Immunother Cancer. 9:. PubMed
  16. Meadows D, et al. 2015. PLoS One. 10: 0143738. PubMed
  17. Weigmann B, et al. 2012. J Allergy Clin Immunol. 129:1126. PubMed
  18. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  19. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  20. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  21. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  22. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  23. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  24. Younes AI, et al. 2021. Transl Oncol. 14:100983. PubMed
  25. Valkenburg S, et al. 2016. Sci Rep. 6:22666. PubMed
  26. Silva DA, et al. 2019. Nature. 565:186. PubMed
  27. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  28. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  29. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  30. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  31. Kumar D, et al. 2018. Cancer Prev Res (Phila). 0.895138889. PubMed
  32. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  33. Mazumder S, et al. 2021. Heliyon. 7:e08124. PubMed
  34. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
  35. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
RRID
AB_313412 (BioLegend Cat. No. 108905) AB_313413 (BioLegend Cat. No. 108906)

Antigen Details

Structure
Integrin α chain, 150 kD
Distribution

NK cells, subset of T cells

Function
Adhesion
Ligand/Receptor
Collagen, laminin
Cell Type
NK cells, T cells
Biology Area
Cell Adhesion, Cell Biology, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Arase H, et al. 2001. J. Immunol. 167:1141.
2. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
3. Sasaki K, et al. 2003. Int. Immunol. 15:701.
4. Inoue O, et al. 2003. J. Cell Biol. 160:769.

Gene ID
16398 View all products for this Gene ID
UniProt
View information about CD49b on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线